Baxter Opens Biologics Production Facility in SingaporeBy
Baxter International Inc. has opened its advanced recombinant biologic facility in Singapore and has announced expansion plans for a new recombinant protein processing suite.
The current suite supports the processing of Advate [antihemophilic factor (recombinant)], a full-length recombinant factor VIII (rFVIII) for treating hemophilia A. The second suite will initially process Rixubis [goagulation factor IX (recombinant)], a recombinant factor IX (rFIX) protein for treating hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment, BAX 855, upon regulatory approval.
The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of Advate, thereby allowing the facility to process and supply Advate to the European Union, Iceland, and Norway. The biologics facility in Singapore currently employs more than 400 production staff and expects to reach 450 by 2015 to support the second processing suite. The facility is the company’s third location supporting Advate production.
Source: Baxter International